RXST
RxSight, Inc.
RXST
4.76USD
+1.71%
Oct 06, 2026
Price
Loading price history…
Price Action
Price trend is broken
Longer-term context reads damaged structure, with a near-term setup of distribution pressure.
The tactical setup reads distribution pressure, but the weekly structure is broken.
EntryDamaged / breakdown
The technical structure itself is broken across timeframes — the weakest entry profile.
Key Financials
- Market Cap
- $198.0M
- Avg Volume (60D)
- 829.1K
- Revenue Growth YoY
- -3.9%
- Gross Margin
- +77.5%
- Operating Margin
- -45.5%
- Free Cash Flow Yield
- -13.7%
- Distance from 200DMA
- -31.3%
- Next Earnings
- 2026-11-04
- P/E
- N/M
60 sessions
FY2025 vs FY2024
Trailing twelve months
Market metrics as of Oct 5, 2026
Financial results for the period ended Jun 30, 2026
Filed balance-sheet data as of Jun 30, 2026
Fundamentals & Valuation
One of the two valuation perspectives says cheap; intrinsic is the dissenting view. The published stance is held at fair because no positive free cash flow behind the low multiple.
RxSight, Inc. has a Fair valuation stance because the price broadly reflects the strength of its balance sheet, with upside and risk reasonably balanced.
Company Research
Thesis
RxSight is a direct, differentiated supplier of adjustable intraocular lenses and the associated light-delivery equipment and procedure workflow used after cataract surgery.
Opportunity
Moderate opportunity
Growing use of higher-value intraocular lenses, surgical systems, and clinical workflows that improve visual outcomes and support elective patient upgrades in cataract and lens-based refractive procedures.
Key risk
Slow adoption of new intraocular lens technology by surgeons.
Narrative & Theme
Premium Cataract and Refractive Procedure Adoption
Part of Premium Intraocular Lenses and Postoperative Vision Customization, with strong fit.
RXST does not fit any promoted active narrative: its demand driver is elective premiumization and technology adoption in ophthalmic surgery, rather than AI, power, defense, minerals, cybersecurity, nuclear, semiconductors, or metabolic disease.
Narrative HeatCooling3.7 / 10
Theme HeatNeutral5.9 / 10
This is the company’s own research reading. The canonical heat measurement for this story has not run.
Business & Markets
Healthcare · Medical Devices
What they do
RxSight develops, manufactures, and sells light adjustable intraocular lenses used in cataract surgery, enabling post-surgical customization of patients' visual acuity through a proprietary light adjustment system.
How it earns
The company generates revenue primarily through transactional sales of its intraocular lenses and related adjustment systems to healthcare providers.
Products & services
RxSight Light Adjustable Lens (LAL)
RxSight Light Adjustment System
Customers & end markets
Ophthalmologists and eye surgeons
Healthcare providers in the United States
Market position
Niche player specializing in light adjustable intraocular lenses within the medical device sector for ophthalmology.
Demand drivers
Low cyclicality
Demand for cataract surgery and related medical devices is relatively stable and driven by demographic trends rather than economic cycles.